GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was KRW 0.00012 million compared to negative sales of KRW 0.0001 million a year ago. Net loss was KRW 6,762.92 million compared to net income of KRW 56,832.5 million a year ago. Basic loss per share from continuing operations was KRW 593 compared to basic earnings per share from continuing operations of KRW 4,980 a year ago. Basic loss per share was KRW 593 compared to basic earnings per share of KRW 4,980 a year ago.